Is SMMT undervalued or overvalued?
As of 2025-03-17, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -1.21 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 20.79 USD, the upside of Summit Therapeutics Inc is -105.80%. This means that SMMT is overvalued by 105.80%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.21 - -1.21 | -1.21 | -105.80% |
| P/E | (2.92) - (3.71) | (2.96) | -114.2% |
| DDM - Stable | (1.53) - (3.63) | (2.58) | -112.4% |
| DDM - Multi | (0.03) - (0.05) | (0.04) | -100.2% |
| Market Cap (mil) | 15,331.59 |
| Beta | 4.45 |
| Outstanding shares (mil) | 737.45 |
| Enterprise Value (mil) | 15,226.72 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.51% |
| Cost of Debt | 5.00% |
| WACC | 8.09% |